標(biāo)題: Titlebook: Antibodies; Volume 1: Production G. Subramanian Book 2004 Springer Science+Business Media New York 2004 HIV.cancer.cancer therapy.developme [打印本頁] 作者: Harrison 時(shí)間: 2025-3-21 16:19
書目名稱Antibodies影響因子(影響力)
書目名稱Antibodies影響因子(影響力)學(xué)科排名
書目名稱Antibodies網(wǎng)絡(luò)公開度
書目名稱Antibodies網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Antibodies被引頻次
書目名稱Antibodies被引頻次學(xué)科排名
書目名稱Antibodies年度引用
書目名稱Antibodies年度引用學(xué)科排名
書目名稱Antibodies讀者反饋
書目名稱Antibodies讀者反饋學(xué)科排名
作者: 語源學(xué) 時(shí)間: 2025-3-21 20:42
Scale-Up of Antibody Purification,anized antibodies Humira (Abbott), Herceptin (Genentech/Roche), Zenapax (Roche/PDL), Mylotarg (Celltech/Wyeth), Campath (Ilex/Schering), Xanelim (Genentech/Xoma) and Avastin (Genentech) or the murine derived antibodies Bexxar (Corixa/GSK), Rituxan (IDEC/Genentech) and Orthoclone (Johnson & Johnson).作者: Dignant 時(shí)間: 2025-3-22 01:28
Einführung in die lokale Publizistikor controlling the downstream processing and the release of the bulk material as well as finished product. For additional information on cell line characterisation refer to the relevant guidelines ICH Q5B and ICH Q5D or Fels, 2001.作者: obstruct 時(shí)間: 2025-3-22 06:37 作者: plasma-cells 時(shí)間: 2025-3-22 10:32
Book 2004must be addressed, and lessons learned must be applied both to current purification methods and to the new technologies that continue to emerge. This book presents an overview of the current advances applied in the manufacture of monoclonal antibody including: .-concepts in development of manufactur作者: 巨頭 時(shí)間: 2025-3-22 15:45
Book 2004ing strategies, .-importance of antibody fragments, .-application of chromatography method development, .-quality control, .-effect of expression on antibody properties, .-virus removal and safety, .-pharmacokinetics, .-regulatory aspects..作者: 鋼筆記下懲罰 時(shí)間: 2025-3-22 18:07 作者: 無關(guān)緊要 時(shí)間: 2025-3-22 21:38
mitations must be addressed, and lessons learned must be applied both to current purification methods and to the new technologies that continue to emerge. This book presents an overview of the current advances applied in the manufacture of monoclonal antibody including: .-concepts in development of 作者: 喃喃訴苦 時(shí)間: 2025-3-23 05:07
Aufgaben und Funktionen der lokalen Medien,esearch as well as for the diagnosis and treatment of a vast array of diseases. This is largely due to the fact that antibodies can be purposedly raised against many natural and synthetic molecules, which they later recognize in a highly specific way, even in very complex matrices.作者: 大方不好 時(shí)間: 2025-3-23 06:33 作者: Jocose 時(shí)間: 2025-3-23 13:47
Die aggregierte Güternachfrage: Yd=yd(P) reduced immunogenicity (Morrison et al., 1984, Morrison, 1985). In an attempt to further reduce immunogenicity, recombinant DNA technology has been used to generate “humanized” mAbs with mouse sequences largely confined to the hypervariable regions.作者: NIP 時(shí)間: 2025-3-23 14:38
Purification of Antibodies by Chromatographic Methods,esearch as well as for the diagnosis and treatment of a vast array of diseases. This is largely due to the fact that antibodies can be purposedly raised against many natural and synthetic molecules, which they later recognize in a highly specific way, even in very complex matrices.作者: figurine 時(shí)間: 2025-3-23 20:36 作者: 糾纏 時(shí)間: 2025-3-23 22:22 作者: GEM 時(shí)間: 2025-3-24 04:35
Spezielle Typen von Minimierungsproblemen,lin, most of the initial wave of biotechnology products launched in the 1980s and 1990s were peptide hormones and enzymes licensed for indications with relatively small patient populations and for short-term rather than chronic use. Consequently, the market requirement for these products was frequently in the low kilogram range.作者: 或者發(fā)神韻 時(shí)間: 2025-3-24 10:17 作者: Compass 時(shí)間: 2025-3-24 12:53 作者: 抑制 時(shí)間: 2025-3-24 15:12 作者: Emasculate 時(shí)間: 2025-3-24 20:25 作者: Axillary 時(shí)間: 2025-3-25 02:36
Spezielle Typen von Minimierungsproblemen,lin, most of the initial wave of biotechnology products launched in the 1980s and 1990s were peptide hormones and enzymes licensed for indications with relatively small patient populations and for short-term rather than chronic use. Consequently, the market requirement for these products was frequen作者: forecast 時(shí)間: 2025-3-25 05:14
Spezielle Typen von Minimierungsproblemen,b) these molecules are now gaining respect again. Among the “Top Twenty” biopharmaceuticals the number of antibodies and related products is increasing. In the pipeline of new biological entities most of the molecules either are murine monoclonal antibodies, chimeric monoclonal antibodies, humanized作者: HALL 時(shí)間: 2025-3-25 07:55 作者: magnate 時(shí)間: 2025-3-25 14:07 作者: 新娘 時(shí)間: 2025-3-25 17:14
Problembereiche der Geld- und Fiskalpolitikspecifically Rhesus positive red blood cells (RBC) prevent the allo-immunisation against RBC and, hence, the h?molytic disease of the new-born (HDN). These anti-Rhesus D antibodies (anti-D) are also used in cases ofthe following cases, abortion, extra-uterine pregnancies, amniocentesis, fetal transp作者: FLIC 時(shí)間: 2025-3-25 20:54 作者: GORGE 時(shí)間: 2025-3-26 02:18
https://doi.org/10.1007/978-3-642-58713-9harmaceuticals. With a significant higher number in clinical trials and the search for new recombinant proteins as a result of the human genome sequencing program it is expected that many more human antibodies will enter the market in years to come (Gura, 2002, Walsh, 2000).作者: 充足 時(shí)間: 2025-3-26 07:30 作者: 從屬 時(shí)間: 2025-3-26 12:22 作者: 整頓 時(shí)間: 2025-3-26 13:32 作者: 音樂會 時(shí)間: 2025-3-26 19:24 作者: SEEK 時(shí)間: 2025-3-26 21:22 作者: 施魔法 時(shí)間: 2025-3-27 05:10
Large-Scale Production of Therapeutic Antibodies: Considerations for Optimizing Product Capture andlin, most of the initial wave of biotechnology products launched in the 1980s and 1990s were peptide hormones and enzymes licensed for indications with relatively small patient populations and for short-term rather than chronic use. Consequently, the market requirement for these products was frequently in the low kilogram range.作者: consolidate 時(shí)間: 2025-3-27 07:39
Contract Manufacturing of Biopharmaceutical Grade Antibodies,harmaceuticals. With a significant higher number in clinical trials and the search for new recombinant proteins as a result of the human genome sequencing program it is expected that many more human antibodies will enter the market in years to come (Gura, 2002, Walsh, 2000).作者: indemnify 時(shí)間: 2025-3-27 13:23 作者: Homocystinuria 時(shí)間: 2025-3-27 17:01 作者: 否認(rèn) 時(shí)間: 2025-3-27 19:47
Einführung in die lineare Algebraain clinical indications. Consequently a variety of antibody fragments and conjugates have been developed that address specific applications and facilitate their production using low cost, microbial expression systems. This chapter will review key considerations in the formatting of antibody fragmen作者: 他一致 時(shí)間: 2025-3-27 23:49 作者: 的闡明 時(shí)間: 2025-3-28 02:44 作者: 隱士 時(shí)間: 2025-3-28 07:21
Antibody Fragments,ain clinical indications. Consequently a variety of antibody fragments and conjugates have been developed that address specific applications and facilitate their production using low cost, microbial expression systems. This chapter will review key considerations in the formatting of antibody fragmen作者: cauda-equina 時(shí)間: 2025-3-28 11:09 作者: SEVER 時(shí)間: 2025-3-28 17:12
Concepts in Development of Manufacturing Strategies for Monoclonal Antibodies, creating an immortal antibody producing cell, a hybridoma (Kohler and Milstein, 1975). Since the first mouse monoclonal antibodies were produced, the idea of using them as therapeutics or “magic bullets” has been viewed as major exploitation of this technology. This is, in part, due to the fact tha作者: 骯臟 時(shí)間: 2025-3-28 21:44
Antibody Fragments,scular and infectious diseases. This is largely due to the development of technologies that enable the generation of antibodies of high specificity and low immunogenicity with relative ease (Maynard and Georgiou, 2000). The specificity of all antibodies is determined by the nature of their binding t作者: Militia 時(shí)間: 2025-3-29 02:15
Large-Scale Production of Therapeutic Antibodies: Considerations for Optimizing Product Capture andlin, most of the initial wave of biotechnology products launched in the 1980s and 1990s were peptide hormones and enzymes licensed for indications with relatively small patient populations and for short-term rather than chronic use. Consequently, the market requirement for these products was frequen作者: Diaphragm 時(shí)間: 2025-3-29 04:38 作者: 自制 時(shí)間: 2025-3-29 09:43 作者: buoyant 時(shí)間: 2025-3-29 12:16
Quality Control of Antibodies for Human Use,international regulatory authorities. The US Food and Drug Administration (FDA) issued a guidance in 1997 specifically for antibody products in its “Points to consider in the manufacture and testing of monoclonal antibody products for human use”. This guideline describes the quality control for the 作者: Goblet-Cells 時(shí)間: 2025-3-29 17:30
